Business
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
ZUG, Switzerland, February 02, 2026--Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aes
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/f5c4c8c0433866291e7a3e2214806936"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yPjcpCYbNa0S2uAtnS4wYw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f5c4c8c0433866291e7a3e2214806936","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.riFEMJjj_HCdNyAEK0KXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f5c4c8c0433866291e7a3e2214806936","width":823,"height":209}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults","length":281,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3","length":258,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":539,"olType":false},{"type":"text","content":"ZUG, Switzerland, February 02, 2026--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs.","length":562,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"padding-left:0.0px;background-color:#CCEEFF;","val":[{"type":"text","content":" ","length":6,"tagName":"p","attribs":{}},{"type":"text","content":""We p...